Lv1
70 积分 2025-10-18 加入
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective anti-fibrotic and anti-inflammatory activity in different models of pulmonary fibrosis
3个月前
已完结
Effect of Admilparant, an LPA1 Antagonist, on Disease Progression in Pulmonary Fibrosis
3个月前
已完结
Computer simulation as a tool for the rapid optimization of the high-performance liquid chromatogrpahic separation of a tryptic digest human growth hormone
3个月前
已完结
Fibroblast activation and heterogeneity in fibrotic disease
4个月前
已完结
Global epidemiology and burden of interstitial lung disease
4个月前
已完结
皖公网安备34019202002308
